Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Abstract Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10–15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXIVA trial demonstrated a 35% VTT response...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Rebecca Wray, Hania Paverd, Ines Machado, Johanna Barbieri, Farhana Easita, Abigail R. Edwards, Ferdia A. Gallagher, Iosif A. Mendichovszky, Thomas J. Mitchell, Maike de la Roche, Jacqueline D. Shields, Stephan Ursprung, Lauren Wallis, Anne Y. Warren, Sarah J. Welsh, Mireia Crispin-Ortuzar, Grant D. Stewart, James O. Jones, On behalf of the NAXIVA Study Group
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Nature Portfolio 2025-04-01
Rangatū:	Nature Communications
Urunga tuihono:	https://doi.org/10.1038/s41467-025-58436-8
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!